Fengyu Zhang
Marco Colizzi
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1Global Clinical and Translational Research Institute, Bethesda, MD, United States
- 2Unit of Psychiatry and Eating Disorders, Department of Medicine (DMED), University of Udine, Udine, Italy
Editorial on the Research Topic
Case reports in autism: 2023
Autism is a neurodevelopmental disorder that appears early in life and may continue into adulthood or throughout life. As an emerging condition, autism has been shown to have high heterogeneity in its etiology, clinical manifestations, and complex co-morbidities which may complicate the process of making appropriate diagnoses and delivering effective interventions. While some antipsychotics (risperidone and aripiprazole) have been approved for the treatment of aggression and irritability in individuals with autism, there has been no approved pharmacological medication for the treatment of autism (1). People have been actively participating in exploring non-pharmacological therapies to mitigate the clinical symptoms, hoping to support the neurodevelopmental trajectory effectively and timely.
This Research Topic publishes eight reports as part of the “Case Report in Autism” series (2). Three reports were on psychiatric co-occurrences with autism and five reports explored novel non-pharmacological interventions on core symptoms or co-morbidities.
Autism has a strong sex bias in diagnosis and girls tend to receive a delayed diagnosis than males due to manifesting symptoms that may not meet existing diagnostic criteria or camouflaging (3). Passarini et al. described clinical and interventional trajectories of a 14-year-old girl who received a late diagnosis of autism with the initial appearance of avoid-restrict food intake disorder (ARFID) and unspecified depression disorder, but normal cognitive functioning. The report provides additional knowledge on the phenotype of female autism. It indicates how psychiatric co-occurrences and normal mental functioning in females could delay the diagnosis and affect timely intervention. Hikikomori is described as a clinical condition of pathological social withdrawal or social isolation that lasts at least more than six months and leads to significant impairment in functioning (4). It was initially defined in the Japanese population as a culture-bound syndrome and now has gained recognition in Western society (5) and may connect with several psychiatric disorders including internet addiction and gaming disorder (6). Carpita et al. reported two adult males with hikikomori, and both had displayed autistic traits since early infancy. However, they did not turn to medical services until developing severe hikikomori-like syndrome that required them to take action. Also, both reported having experienced internet gaming during the social withdrawal before. These suggest that autism may lead to the development of psychiatric co-morbidity with hikikomori and internet gaming disorder if not diagnosed and intervened early. After pharmacological treatment, the two cases had improvement in anxiety and mood conditions and reduced social withdrawal and computer gaming time.
The 20q11.21 duplication is known to cause some developmental features (e.g., metopic ridging/trigonocephaly, epicanthal folds, short hands), and developmental delay or syndromic disorders such as Borhing-Opitz syndrome (7). Simoncini et al. reported a 24-year-old woman with a 350kb microduplication at 20q11.21, which segregates in her father and siblings including twin brothers and two sisters, all of whom have presented either subthreshold or full ASD along with other neurodevelopmental or psychiatric disorders such as bipolar, intellectual disability. This genomic region is known to harbor six protein-coding genes.
Immune dysregulation has been widely associated with clinical symptoms or co-morbidity of autism (8). Meanwhile, the endocannabinoid system has recently received great attention for its pharmacological functions of immunoregulation and neuromodulation in multiple physiological and cognitive processes, and two endocannabinoid receptors are expressed in both the central and peripheral nervous system (9). Bortoletto et al. conducted a monotherapy of ultra-micronized-palmitoylethanolamide in two autistic adult females with different levels of severity. One patient showed improvement in depressive symptoms and social engagement, a trend toward reduced inflammatory response, and enhanced endocannabinoid signaling at a 12-week follow-up. In contrast, the severe patient with moderate intellectual disability was observed with a largely stable psychosocial functioning and no change in immune response and endocannabinoid levels, but suddenly became deteriorating and required antipsychotic medications after 12 weeks; no side effects were observed in both cases.
The next four reports focused on non-pharmacological interventions in autism. Maggio et al. presented a nine-year-old girl with autism whose food consumption was primarily restricted to liquid or semi-liquid and who had little success in a private treatment of food selectivity. Following a multicomponent intervention protocol and an AB-type experimental design, they introduced semi-solid and new foods and observed a noted improvement in food acceptance with little behavioral problems at mealtime.
Digital tools have recently gained popularity for measurement and intervention in individuals with autism (10). Receptive language skill involving auditory-visual conditional discrimination is the ability to understand and respond to spoken language, which poses a significant challenge in individuals with autism. The Green’s conditional-only approach has been considered a more reliable and efficient teaching method for autism (11). Minutoli et al. compared the stimulus presentations using flashcards and digital (tablet) platforms in a six-year-old boy with autism and found that the child responded to flashcards faster and more accurately than Tablet slide presentations before reaching a non-error trial. While this is consistent with a previous case study of three participants in comparing three different teaching methods (12), a formal study is needed before a conclusion is drawn. In contrast, Mavritsakis reported that a 15-year-old male with autism had noted improvements in communication and social interaction after the effective introduction of augmentative and alternative communication devices, starting from a letter board and subsequently transitioning to digital platforms such as iPad applications.
Sensory atypicality is prevalent in autism and sensory reactivity and autistic traits are highly heritable and moderately correlated (13). Hyperacusis in individuals with autism often causes emotional distress in their daily lives (14), and there are no proven effective interventions available. Carson et al. introduced cognitive behavioral therapy with exposure, proven effective in reducing anxiety and distress, to treat hyperacusis in an 11-year-old boy with a pervasive developmental disorder not otherwise specified (PDD-NOS), a measurable improvement in auditory sensory domains and tolerance for some noise encountered during his daily life.
In summary, this Research Topic reported psychiatric co-occurrence with autism, some of which could delay the diagnosis of autism and require timely intervention; several novel intervention strategies including digital tools were tried to mitigate the core symptoms and co-morbidity of autism.
Author contributions
FZ: Writing – original draft, Writing – review & editing. MC: Writing – original draft, Writing – review & editing.
Conflict of interest
MC has been a consultant/advisor to GW Pharma Limited, GW Pharma Italy SRL, and F. Hoffmann-La Roche Limited outside of this work.
The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Rast JE, Anderson KA, Roux AM, Shattuck PT. Medication use in youth with autism and attention-deficit/hyperactivity disorder. Acad Pediatr. (2021) 21:272–9. doi: 10.1016/j.acap.2020.05.015
2. Colizzi M, Zhang F. Editorial: Case reports in autism. Front Psychiatry. (2024) 15. doi: 10.3389/fpsyt.2024.1357823
3. Hull L, Petrides KV, Mandy W. The female autism phenotype and camouflaging: a narrative review. Rev J Autism Dev Disord. (2020) 7:306–17. doi: 10.1007/s40489-020-00197-9
4. Kato TA, Kanba S, Teo AR. A 39-year-old “Adultolescent”: understanding social withdrawal in Japan. Am J Psychiatry. (2016) 173:112–4. doi: 10.1176/appi.ajp.2015.15081034
5. Orsolini L, Bellagamba S, Volpe U, Kato TA. Hikikomori and modern-type depression in Italy: A new phenotypical trans-cultural characterization? Int J Soc Psychiatry. (2022) 68:1010–7. doi: 10.1177/00207640221099408
6. Kato TA, Shinfuku N, Tateno M. Internet society, internet addiction, and pathological social withdrawal: the chicken and egg dilemma for internet addiction and hikikomori. Curr Opin Psychiatry. (2020) 33:264–70. doi: 10.1097/YCO.0000000000000601
7. Avila M, Kirchhoff M, Marle N, Hove HD, Chouchane M, Thauvin-Robinet C, et al. Delineation of a new chromosome 20q11.2 duplication syndrome including the ASXL1 gene. Am J Med Genet A. (2013) 161a:1594–8. doi: 10.1002/ajmg.a.35970
8. Robinson-Agramonte MLA, Noris García E, Fraga Guerra J, Vega Hurtado Y, Antonucci N, Semprún-Hernández N, et al. Immune dysregulation in autism spectrum disorder: what do we know about it? Int J Mol Sci. (2022) 23:1–25. doi: 10.3390/ijms23063033
9. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res. (2009) 60:85–92. doi: 10.1016/j.phrs.2009.03.019
10. Pandina G. The role of digital medicine in autism spectrum disorder. Eur Neuropsychopharmacol. (2021) 48:42–4. doi: 10.1016/j.euroneuro.2021.02.016
11. Grow LL, Carr JE, Kodak TM, Jostad CM, Kisamore AN. A comparison of methods for teaching receptive labeling to children with autism spectrum disorders. J Appl Behav Anal. (2011) 44:475–98. doi: 10.1901/jaba.2011.44-475
12. Holmes EJ, Eikeseth S, Schulze KA. Teaching individuals with autism receptive labeling skills involving conditional discriminations: A comparison of mass trial and intermixing before random rotation, random rotation only, and combined blocking. Res Autism Spectr Disord. (2015) 11:1–12. doi: 10.1016/j.rasd.2014.11.013
13. Taylor MJ, Gustafsson P, Larsson H, Gillberg C, Lundström S, Lichstenstein P. Examining the association between autistic traits and atypical sensory reactivity: A twin study. J Am Acad Child Adolesc Psychiatry. (2018) 57:96–102. doi: 10.1016/j.jaac.2017.11.019
Keywords: autism, cannabinoid system, digital medicine, autism co-morbidity, cognitive behavioral therapy
Citation: Zhang F and Colizzi M (2025) Editorial: Case reports in autism: 2023. Front. Psychiatry 16:1563977. doi: 10.3389/fpsyt.2025.1563977
Received: 20 January 2025; Accepted: 31 January 2025;
Published: 17 February 2025.
Edited and Reviewed by:
Antonio Narzisi, Stella Maris Foundation (IRCCS), ItalyCopyright © 2025 Zhang and Colizzi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fengyu Zhang, emhhbmdmeUBnY2F0cmVzZWFyY2gub3Jn